Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Sellas Life Sciences Group
American Regent, Inc.
University of California, Davis
IGM Biosciences, Inc.
Prelude Therapeutics
Hackensack Meridian Health
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AbbVie
M.D. Anderson Cancer Center
National Cancer Institute (NCI)